Reg. name: Rydapt®
Class: Multi-targeted Tyrosine Kinase Inhibitor (TKI)
RYDAPT® is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation positive, as detected by a FDA approved test.
RYDAPT® is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive
Reg. name: Vidaza
Class: Hypomethylating agent
The Summary of Product Characteristics for Vidaza® states that the antineoplastic effects of azacitidine are thought to be achieved through various mechanisms. These include a cytotoxic effect on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. In addition, inhibition of DNA, RNA, and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
- Vidaza® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/21508. [Accessed January 2017].
VIDAZA® is indicated for the treatment of adult patients who are not eligible for Haematopoietic Stem Cell Transplantation (HSCT) with Acute Myeloid leukemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification